Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) were up 20.9% during trading on Thursday . The stock traded as high as C$0.28 and last traded at C$0.26. Approximately 727,571 shares were traded during trading, an increase of 14% from the average daily volume of 639,245 shares. The stock had previously closed at C$0.22.
Hemostemix Trading Up 12.7 %
The firm has a fifty day moving average of C$0.11 and a two-hundred day moving average of C$0.08. The company has a market capitalization of C$27.01 million, a PE ratio of -15.50 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- How to Invest in the FAANG Stocks
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
